Pidotimod vs Thymosin Alpha-1 — Peptide Comparison

Pidotimod vs Thymosin Alpha-1 — Peptide Comparison Pidotimod vs Thymosin Alpha-1 — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Pidotimod 400–800 mg Thymosin Alpha-1 1.6–3.2 mg Frequency Multiple times daily Twice weekly Administration Oral (tablet) Subcutaneous injection Cycle Length 12+ weeks 8-12 weeks Onset Speed Moderate (1-2 weeks) Evidence Level Moderate human trials (Phase 1-2) Efficacy Immune Healing & Recovery Anti-Aging Immune Activation Infection Fighting Immune Balance Technical Data Molecular Formula C9H12N2O4S Molecular Weight 244.27 g/mol Half-Life Approximately 4 hours Bioavailability ~45% (oral) CAS Number 121808-62-6 C129H215N33O55 3108.32 g/mol Approximately 2 hours High when injected subcutaneously (rapid absorption, peak at ~2 hours) 62304-98-7 Protocols starting 400 mg (pediatric, age >3 yr): twice daily for acute infection, once daily for prevention Twice daily (acute) or once daily (prevention) 15-20 days acute; up to 60 days for prevention Approved pediatric dosing (Italy/Asia; not FDA-approved). Take 2 hours before or after food to preserve absorption. [2][6] standard 800 mg (adults): twice daily for acute infection, once daily for prevention Twice daily (acute) or once daily (prevention/maintenance) 8-15 days acute; up to ~60 days for prophylaxis Standard adult dosing for acute respiratory infection with antibiotics, then once-daily maintenance. Take away from meals. [5][6] 1.6 mg Twice weekly (3-4 days apart) 6-12 months Established clinical dose for thymalfasin (Zadaxin); body-surface-scaled as 900 mcg/m2 [4][6]. Phase III chronic hepatitis B trials used 1.6 mg SC twice weekly for 6-12 months [4]. advanced 1.6 mg daily, then 1.6 mg twice weekly Daily for an initial loading period, then twice weekly Some immune-adjuvant and acute protocols front-load with daily dosing before settling to the standard twice-weekly schedule [4][6]. Applications Recurrent Respiratory Infections Pidotimod is specifically indicated and most widely studied for preventing recurrent respiratory tract infections (RRTIs), particularly in children over 3 years. Multiple clinical studies and a Phase 4 trial with 338 children have demonstrated significant reductions in infection frequency and duration. Immunocompromised Patients Patients with documented cell-mediated immunodepression, including those with HIV or the elderly with weakened immune function, may benefit from pidotimod's ability to enhance T-cell function and rebalance cytokine production. Seasonal Immune Support Preventive courses before cold and flu season can strengthen immune defenses through TLR activation and enhanced mucosal immunity (increased salivary IgA), reducing susceptibility to viral respiratory infections. Chronic Respiratory Conditions Patients with chronic bronchitis, bronchiectasis, or COPD who experience frequent exacerbations may benefit from pidotimod as an adjunctive therapy to reduce infection-triggered flares. Chronic Hepatitis B or C Support Thymosin Alpha-1 has its strongest clinical evidence here. Multiple trials show it helps clear viral loads and normalize liver enzymes, especially when combined with antiviral medications. It's approved in over 30 countries specifically for hepatitis treatment. Cancer Treatment Support When used alongside chemotherapy, Thymosin Alpha-1 may help maintain immune function that chemo tends to suppress. Research in lung cancer, melanoma, and liver cancer shows improved outcomes when added to standard treatments. It helps your immune system keep fighting even during tough treatments. Age-Related Immune Decline As you age, your thymus shrinks and produces less thymosin naturally—a process called immunosenescence. Supplementing with Thymosin Alpha-1 may help compensate, keeping your immune defenses more youthful and responsive. Think of it as replacing what your body makes less of over time. Severe Infection Recovery In sepsis and critical infections, Thymosin Alpha-1 has shown promise for reducing mortality by helping restore immune balance. It's particularly interesting because it modulates immunity rather than just boosting it—calming overreaction while enhancing pathogen-fighting ability. Safety Profile Common Gastrointestinal discomfort Skin rash Headache Nausea Diarrhea Transient fever Uncommon Allergic reaction Serious Severe hypersensitivity reaction Injection site reactions Mild fatigue Flu-like symptoms Mild fever Lymph node awareness Research Status FDA Status Research compound Safety Overview Pidotimod (immuno-stimulating dipeptide analog) has 40+ years of safety data in European/Asian markets with favorable tolerability profile. Mild gastrointestinal effects occur in <5% of users; no serious adverse events in 25 years of clinical use across 50,000+ patient population. Oral bioavailability excellent with rapid intestinal absorption. No mutagenicity or carcinogenicity in preclinical testing; immunomodulatory mechanism carries theoretical risk in severely immunocompromised patients. Contraindications xKnown hypersensitivity to pidotimod or any excipients xPregnancy and breastfeeding (insufficient safety data) xChildren under 3 years of age xSevere autoimmune disease in active flare FDA approved for other use Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it doesn't accumulate in your system. It's been used safely in thousands of patients with hepatitis, cancer, and other serious conditions. xOrgan transplant recipients on immunosuppressants xActive autoimmune disease flares xKnown allergy to thymosin peptides xPregnancy or breastfeeding xChildren under 18 without medical supervision Decision Guide Choose Pidotimod if... Preventing recurrent respiratory tract infections Supporting immune function in immunocompromised individuals Reducing frequency of infections in children and elderly Immune support during HIV management Choose Thymosin Alpha-1 if... Immune system strengthening Chronic infection support Cancer adjunct therapy Healthy aging immune support